Boston Scientific Corporation (BSX)
Market Cap | 150.86B |
Revenue (ttm) | 15.91B |
Net Income (ttm) | 1.79B |
Shares Out | 1.47B |
EPS (ttm) | 1.21 |
PE Ratio | 84.67 |
Forward PE | 37.74 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 4,504,011 |
Open | 103.40 |
Previous Close | 103.04 |
Day's Range | 102.32 - 103.60 |
52-Week Range | 64.08 - 103.60 |
Beta | 0.80 |
Analysts | Strong Buy |
Price Target | 98.95 (-3.33%) |
Earnings Date | Feb 5, 2025 |
About BSX
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, c... [Read more]
Financial Performance
In 2023, Boston Scientific's revenue was $14.24 billion, an increase of 12.29% compared to the previous year's $12.68 billion. Earnings were $1.57 billion, an increase of 144.55%.
Financial StatementsAnalyst Forecast
According to 22 analysts, the average rating for BSX stock is "Strong Buy." The 12-month stock price forecast is $98.95, which is a decrease of -3.33% from the latest price.
News
Top 4 Health Care Stocks You May Want To Dump In Q1
As of Jan. 21, 2025, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Late-breaking data presented at AF Symposium 2025 highlight key Boston Scientific therapies for management of patients with atrial fibrillation
First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSE™ Pulsed Field Abl...
Boston Scientific Jumps Ahead of Earnings
Boston Scientific Corporation (BSX) shares rise on acquisitions – earnings due in early February.
Stocks on the move: Delta, Constellation Energy, Wynn, Sweetgreen and Boston Scientific
The Investment Committee discuss some stocks on the move today.
Final Trades: Apollo, UnitedHealth, Boston Scientific and the IYF
The Investment Committee give you their top stocks to watch for the second half.
Boston Scientific Expands Cardiovascular Treatment Portfolio With $440 Million+ Bolt Medical Deal
On Wednesday, Boston Scientific Corporation BSX agreed to acquire Bolt Medical, Inc., the developer of an intravascular lithotripsy (IVL) advanced laser-based platform for coronary and peripheral arte...
Boston Scientific Announces Agreement to Acquire Bolt Medical, Inc.
Acquisition to expand cardiovascular portfolio with complementary and differentiated calcium modification platform, furthering company's strategy to address coronary and peripheral disease MARLBOROUGH...
Boston Scientific Announces Participation in the J.P. Morgan Healthcare Conference and Conference Call Discussing Fourth Quarter 2024 Results
MARLBOROUGH, Mass. , Jan. 2, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 43rd Annual J.P.
Boston Scientific Corporation: Solid Financials And Upward Continuation
Boston Scientific closes the year at historic highs, with investors refusing to liquidate even at these levels. The smooth upward movement of the stock indicates the quality of its investor base. Stro...
FDA classifies recall of Boston Scientific catheters as 'most serious'
The U.S. Food and Drug Administration on Wednesday classified a recall of Boston Scientific's catheters used in a type of minimally invasive surgery as "most serious".
Boston Scientific CMO Discuss Solutions for Health Inequality on Today's Marketplace
NEW YORK , Dec. 11, 2024 /PRNewswire/ -- Today's Marketplace (TMP) is proud to announce a featured interview with Boston Scientific (NYSE: BSX) Global Chief Medical Officer, Kenneth Stein, MD, and Sco...
Jim Cramer talks companies that joined the $100 billion club this year
'Mad Money' host Jim Cramer looks at companies that joined the $100 billion club this year.
Boston Scientific Announces Agreement to Acquire Intera Oncology® Inc.
Acquisition to expand interventional oncology offerings with complementary therapy to treat liver-dominant metastases MARLBOROUGH, Mass. , Nov. 25, 2024 /PRNewswire/ -- Boston Scientific Corporation (...
Why Is Medical Device Giant Boston Scientific Stock Trading Higher On Monday?
On Saturday, Boston Scientific Corporation BSX unveiled three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device.
Boston Scientific WATCHMAN FLX™ Left Atrial Appendage Closure Device Demonstrates Superior Bleeding Risk Reduction to Oral Anticoagulation Following a Cardiac Ablation in the OPTION Clinical Trial
Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation MARLBOROUGH, Mass. and CHICAGO , ...
Boston Scientific Corporation (BSX) UBS Global Healthcare Conference (Transcript)
Boston Scientific Corporation (NYSE:BSX) UBS Global Healthcare Conference November 12, 2024 10:15 AM ET Company Participants Jonathan Monson - Senior Vice President, Investor Relations Nick Spadea-An...
Boston Scientific Closes Acquisition of Axonics, Inc.
MARLBOROUGH, Mass. , Nov. 15, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: AXNX), a medical technology company ...
Kidney Stone Management Market Forecast Report, 2024-2032 - Cook Group, Richard Wolf, Boston Scientific, and Dornier MedTech Actively Engaged in M&As to Increase Share
Dublin, Nov. 07, 2024 (GLOBE NEWSWIRE) -- The "Kidney Stone Management Market Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering. The global market size for kidn...
Boston Scientific to Participate in the 2024 UBS Global Healthcare Conference
MARLBOROUGH, Mass. , Nov. 5, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 2024 UBS Global Healthcare Conference on Tuesday, November 12, 2024.
Boston Scientific Announces Agreement to Acquire Cortex, Inc.
Acquisition to complement electrophysiology portfolio with solution to advance the treatment of complex atrial fibrillation MARLBOROUGH, Mass. , Nov. 4, 2024 /PRNewswire/ -- Boston Scientific Corporat...
Boston Scientific Corporation (BSX) Business Update Earnings Call Transcript
Boston Scientific Corporation (NYSE:BSX) Business Update Earnings Conference Call October 30, 2024 4:00 PM ET Company Participants Jonathan Monson - Senior Vice President of Investor Relations Joseph...
Why The Fundamentals Make Me Bullish On Boston Scientific
Medical devices maker Boston Scientific should continue to grow profitably through the next several years. Backing that bullishness is its history, good margins, pipeline, capital allocation, and more...
Why is Boston Scientific Stock Trading Lower On Wednesday?
On Wednesday, Boston Scientific Corporation BSX released the results of the primary endpoint of the ACURATE IDE trial of ACURATE neo2 Aortic Valve System for patients with severe, symptomatic aortic s...
ACURATE neo2™ Aortic Valve System Data Presented at Late-Breaking Clinical Trial Session at TCT 2024
MARLBOROUGH, Mass. and WASHINGTON , Oct. 30, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the results of the primary endpoint of the ACURATE IDE clinical trial, which...